What Harpoon Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Robbins Andrews R | Director | Mar 11 | Disposition to Issuer · D | −5,000 | — | — | 0 |
| Myers Scott Dunseth | Director | Mar 11 | Disposition to Issuer · D | −22,665 | — | — | 0 |
| Silvernail Lauren P | Director | Mar 11 | Disposition to Issuer · D | −5,000 | — | — | 0 |
| Chin Mark | Director | Mar 11 | Disposition to Issuer · D | −13,224 | — | — | 0 |
| Walker Luke Nathaniel | Chief Medical Officer | Mar 11 | Disposition to Issuer · D | −135,000 | — | — | 0 |
| Merck & Co., Inc. | 10% owner | Mar 11 | Open-market buy · P | +21,397,205 | $23.00 | +$492M | 1,000 |
| Drachman Jonathan G | Director | Mar 11 | Disposition to Issuer · D | −5,415 | — | — | 0 |
| Eastland Julia Marie | President and CEO | Mar 11 | Disposition to Issuer · D | −269,381 | — | — | 0 |
| Eastland Julia Marie | President and CEO | Mar 11 | Grant / award · A | +31,250 | — | — | 269,381 |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | Mar 11 | Disposition to Issuer · D | −18,734 | — | — | 0 |
| Bailes Joseph S | Director | Mar 11 | Disposition to Issuer · D | −5,000 | — | — | 0 |
| Hunt Ronald | Director | Mar 11 | Disposition to Issuer · D | −10,000 | — | — | 0 |
| Hunt Ronald | Director | Mar 11 | Disposition to Issuer · D | −395,783 | — | — | 0 |
| Hunt Ronald | Director | Mar 11 | Disposition to Issuer · D | −1,463,386 | — | — | 0 |
| Hunt Ronald | Director | Mar 11 | Disposition to Issuer · D | −13,224 | — | — | 0 |
| New Leaf Biopharma Opportunities II, L.p. | Director | Mar 11 | Disposition to Issuer · D | −10,000 | — | — | 0 |
| New Leaf Biopharma Opportunities II, L.p. | Director | Mar 11 | Disposition to Issuer · D | −395,783 | — | — | 0 |
| New Leaf Biopharma Opportunities II, L.p. | Director | Mar 11 | Disposition to Issuer · D | −1,463,386 | — | — | 0 |
| Chin Mark | Director | Mar 08 | Grant / award · A | +424 | — | — | 13,224 |
| Drachman Jonathan G | Director | Mar 08 | Grant / award · A | +415 | — | — | 5,415 |
Loading...
